Townsend Richard Nolan 4
4 · Lexeo Therapeutics, Inc. · Filed Oct 17, 2025
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-10-17$8.94/sh−12,985$116,021→ 242,266 total - Award
Common Stock
2025-10-15+33,000→ 255,251 total - Sale
Common Stock
2025-10-17$9.56/sh−148$1,415→ 242,118 total
Footnotes (4)
- [F1]Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").
- [F2]This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]Includes 131,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.